title: Management of deep venous thrombosis and pulmonary embolism.
abstract: The management of deep venous thrombosis (DVT) and pulmonary embolism (PE) is changing dramatically. The US Food and Drug Administration has approved outpatient treatment of DVT with the low-molecular-weight heparin enoxaparin as a bridge to warfarin. Warfarin use is improved by avoiding loading doses and by recognizing previously unappreciated interactions and potentiation with commonly used medications such as acetaminophen. The importance of isolated calf and upper-extremity venous thromboses has been validated, so that patients with these conditions routinely undergo anticoagulation. Risk stratification for PE is becoming more sophisticated because practitioners now assess right ventricular function (usually by echocardiography) instead of relying solely on systemic arterial blood pressure and heart rate to determine prognosis. Among patients with massive DVT or hemodynamically unstable PE, thrombolysis, thrombectomy, and embolectomy (often performed in an interventional angiography laboratory) are being used with increasing skill and improved outcomes.
authors.affiliation: Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. sgoldhaber@partners.org
authors.forename: S Z
authors.initials: SZ
authors.lastname: Goldhaber
mesh_terms: D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*